Richard Knox

Since he joined NPR in 2000, Knox has covered a broad range of issues and events in public health, medicine, and science. His reports can be heard on NPR's Morning Edition, All Things Considered, Weekend Edition, Talk of the Nation, and newscasts.

Among other things, Knox's NPR reports have examined the impact of HIV/AIDS in Africa, North America, and the Caribbean; anthrax terrorism; smallpox and other bioterrorism preparedness issues; the rising cost of medical care; early detection of lung cancer; community caregiving; music and the brain; and the SARS epidemic.

Before joining NPR, Knox covered medicine and health for The Boston Globe. His award-winning 1995 articles on medical errors are considered landmarks in the national movement to prevent medical mistakes. Knox is a graduate of the University of Illinois and Columbia University. He has held yearlong fellowships at Stanford and Harvard Universities, and is the author of a 1993 book on Germany's health care system.

He and his wife Jean, an editor, live in Boston. They have two daughters.

Saturday marks an important milestone in public health – the 50th anniversary of the first Surgeon General's Report on Smoking and Health.

Few if any documents have had the impact of this one — both on the amount of disease and death prevented, and on the very scope of public health.

Federal regulators this month opened a new era in the treatment of a deadly liver virus that infects three to five times more people than HIV. Now the question is: Who will get access to the new drug for hepatitis C, and when?

The drug Sovaldi will cost $1,000 per pill. A typical course of treatment will last 12 weeks and run $84,000, plus the cost of necessary companion drugs. Some patients may need treatment for twice as long.

Enrollment is picking up in new health insurance marketplaces. But the 365,000 who've signed up as of November 30 is a fraction of just one high-visibility group – those whose previous insurance has been cancelled because it didn't meet Affordable Care Act standards.

They're people like Doug Normington, a 58-year-old self-employed videographer in Madison, Wis., who has struggled to buy new insurance since late October.

Researchers say they are achieving success in curing the genetic defect that causes some children to be born without immune defenses, a rare condition made famous in the 1970s by a Texas boy who lived most of his short life in a sterile "bubble."

Scientists now report that 8 out of 9 young children given gene therapy for a type of severe combined immunodeficiency disease, called SCID-X1, are alive and living amid the everyday microbial threats that would otherwise have killed them. The oldest is just over 3 years old.

HIV has reappeared in the blood of two Boston patients who scientists had hoped had been cured of their infections.

This disappointing development, reported by The Boston Globe's Kay Lazar, is yet another cautionary tale of how researchers can never afford to underestimate the human immunodeficiency virus's ability to hide out in patients' bodies and overcome their most ingenious efforts to eliminate it.